Latest publications
-
April 28, 2025 DDB1 engagement defines the selectivity of S656 analogs for cyclin K degradation over CDK inhibition.
Moison C, Mendoza-Sanchez R, Gracias D, Schuetz DA, Spinella JF, Girard S, Thavonekham B, Chagraoui J, Durand A, Fortier S, MacRae T, Bonneil E, Rose Y, Mayotte N, Boivin I, Thibault P, Hébert J, Ruel R, Marinier A, Sauvageau G
EMBO Rep 2025-04-28 ; -
April 20, 2025 MARC, a novel modular chimeric antigen receptor, improves T cell-based cancer immunotherapies by preventing early T cell exhaustion and enhancing persistence.
Tual M, Bellemare-Pelletier A, Moore S, Guipouy D, Farzam-Kia N, Jafarzadeh L, Quenneville J, Barrette B, Saba-El-Leil MK, Delisle JS, Gagnon E
J Immunother Cancer 2025-04-20 ;13( 4 ): -
April 14, 2025 IL1RAP is an immunotherapeutic target for normal karyotype triple-mutated acute myeloid leukemia.
Métois A, Bordeleau ME, Theret L, Hajmirza A, Moujaber O, Spinella JF, Chagraoui J, Mayotte N, Boivin I, Audemard E, Aubert L, Lisi V, Khakipoor B, Farah A, Bonneil E, Robert A, Lippens J, Moraitis A, Béliveau F, Feghaly A, Boucher G, Marcotte R, Gendron P, Thibault P, Lemieux S, Richard-Carpentier G, Lavallée VP, Hébert J, Roux PP, Sauvageau G
Biomark Res 2025-04-14 ;13( 1 ):61 -
April 9, 2025 DEK::NUP214 acts as an XPO1-dependent transcriptional activator of essential leukemia genes.
Kaya F, Bewicke-Copley F, Miettinen JJ, Casado P, Leddy E, Deniz O, Lavallée VP, Philippe C, Zheng J, Grebien F, Khan N, Krizsán S, Saad J, Nolin-Lapalme A, Hébert J, Lemieux S, Audemard E, Matthews J, Grantham M, Di Bella D, Wennerberg K, Parsons A, Gribben J, Cavenagh JD, Freeman SD, Bödör C, Sauvageau G, Wang J, Llamas-Sillero P, Cazier JB, Taussig DC, Bonnet D, Cutillas PR, Heckman CA, Fitzgibbon J, Rouault-Pierre K, Rio-Machin A
Leukemia 2025-04-09 ; -
April 3, 2025